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1. Introduction  
Cancer management has experienced an important progress in the last years due to the 
discovery of new treatments and an improvement in the early detection methods. These 
improvements have had an important repercussion in patients´ life span, having an impact 
in both time and quality life (Berardi et al., 2009). At the same time, knowledge of the 
specific characteristics of each tumor has led us, in recent times, to be aware of the need of 
study the unique identity of the cancer (Li & Lai, 2009).  
For rectal cancer patients, 5-fluorouracil (5-FU)- based chemoradiotherapy before total 
mesorectal excision (TME) is the gold standard treatment for stage II and III (Sauer et al., 2004; 
Wheeler et al., 2004), but the overall rate of response is still about 46-74% (Wheeler et al., 2004; 
Chen et al.,1994)  Research has focused in the discovery of more specific treatments for each 
cancer and, at the same time, has tried to identify the particular features of cancer cells with the 
purpose of design target drugs for these cells in order to avoid affect normal cells. Recently, 
several studies aim at adding to this regimen several different currently available 
chemotherapeutics in colon cancer treatment, such as the 5-FU prodrug, capecitabine 
(Carlomagno et al., 2009; Ugidos et al., 2009), oxaliplatin (Carlomagno et al., 2009), irinotecan 
(Ugidos et al., 2009), cetuximab (Bertolini et al., 2009) or bevacizumab (Willett et al., 2009). 
But these treatments are not devoid of adverse effects that could put at risk patients lives 
due to the treatment itself, so, in these state of affairs,there is a need for identify patients that 
are going to experience important adverse effects or try to recognize the patients in which 
the drug benefits will be more than the adverse effects produced; with this purpose, 
pharmacogenomics and more specific pharmacogenetics studies arise, that so far, have a 
bright and a dark side. 
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In the bright side, there are a few markers with consistent results across studies. Regarding 
oncology field, hematology has been the pharmacogenomic area with the more important 
improvement, being several drugs developed for the treatment of different leukemias 
depending on the genetic of the disease. Development of the first target drug Gleevec 
supposed an important advance for Chronic Myeloid Leukemia treatment (Buchdunger et 
al., 1996), and detection of mutations that confer drug resistance (von Bubnoff et al., 2002) 
allowed to switch to a most favorable treatment depending on the patients´ 
pharmacogenetics (Hiwase et al., 2011).  
Concerning to colorectal cancer treatment and even though it is still necessary to establish a 
definitive pattern across populations and an extensive research is being realized in that field. 
From these researches, it has been establish that one of the markers more studied and whose 
pharmacogenetic association has been more consistently replicated, is high risk of 
developing severe irinotecan toxicity due to a deficiency in the detoxifying enzyme UGT1A1 
(Innocenti et al., 2004; Fujiwara et al., 2010). 
Another important detoxifying enzyme related to colorectal cancer treatment is 
dihydropyrimidine dehydrogenase (DPD). DPD deficiency, the main enzyme related to  5-
fluorouracil catabolism, is associated to severe toxicity, patients with this protein deficiency 
experience mucositis, neutropenia and neurological symptoms under treatment (Johnson & 
Diasio, 2001; Van Kuilenburg, 2004). 
1.1 Germline vs tumoral tissue in pharmacogenetics 
But, despite the existence of solid studies supporting the relationship between germline 
polymorphisms and toxicity of treatment, the efforts of pharmacogenetics studies trying to 
get information of treatment efficiency from germline polymorphisms have not been as 
rewarded (Contopoulos-Ioannidis et al., 2006). 
One of the genes more studied, mainly related to treatment efficiency but also toxicity is 
TYMS gene. Polymorphisms in this gene have been associated to different gene expression 
degree and this to a different protein level (Horie et al., 1995; Kawakami et al., 2001; 
Mandola et al., 2003, 2004). Although numerous studies have indicated association of 
germline low-expression alleles in this gene to an increase survival in patients undergoing 
treatment with 5-Fluorouracil (Mandola et al., 2003; Kawakami & Watanabe, 2003), 
contradictory results and even no association have been reported. (Showalter et al., 2008)  
So far, the only pharmacogenetics markers label by the FDA in colorectal cancer treatments 
for their study, prior to drug administration, are tumoral expression of EGFR measure by 
immunohistochemical and KRAS mutation in codon 12 or 13 (FDA, 2011).  
Germline pharmacogenetics studies of efficiency are based on the premise of non mutability 
of the markers in the tumor (McWhinney & McLeod, 2009), nevertheless, being cancer a 
disease resulting from accumulation of mutations which drives its progression, such 
assumption, does not appear to have any evidence based support neither from an 
experimental or literature point of view (Biankin & Hudson, 2011). 
To date there is 70 drugs with pharmacogenomic biomarkers in drug labels approved by the 
FDA. Of these, 21 are oncology- hematology drugs. In Table 1 is shown the kind of 
information acquired from each gene and the tissue required for its study (FDA, 2011).     
The table reflects the utility of the analysis performed in blood related to toxicity but it is 
noticeable to point out that the FDA recommendations state the necessity of analyze the 
tumor tissue when performing studies of effectiveness. It remarkable to highlight too, that 
just a few genes (EGFR, KRAS, Estrogen receptor, Her2/neu and C-kit) are used as 
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pharmacogenetic markers of effectivity in solid tumors, which indicates that just the 
association of these genes have been consistently replicated across the studies. 
 
Drug  Related to Tissue 
analyzed 
Biomarker FDA recommendation 
 
Arsenic Trioxide 
  
PML/RARα 
translocation 
Positive for PML/RAR-alpha. Effectivity Blood 
 
Busulfan 
  
 Chr. Ph Positive for Philadelphia chromosome. Effectivity Blood 
Capecitabine   
 DPD Contraindicated in patients with known 
dihydropyrimidine dehydrogenase (DPD) 
deficiency. 
Toxicity Blood 
Cetuximab   
 EGFR Colorectal cancer. Immunohistochemical evidence 
of EGFR tumor expression 
Effectivity Tumor 
 KRAS Use of Erbitux is not recommended for the 
treatment of colorectal cancer with KRAS mutations 
in codon 12 or 13 
Effectivity Tumor 
Dasatinib   
 Ph+ Positive for Philadelphia chromosome. Effectivity Blood 
Erlotinib   
 EGFR Patients with EGFR immunohistochemistry (IHC) 
positive tumors. 
Effectivity Tumor 
Fulvestrant   
 Estrogen 
receptor 
Hormone receptor positive metastatic breast cancer. Effectivity Tumor 
 
Gefitinib 
  
 EGFR Positive for EGFR Effectivity Tumor 
Imatinib   
 C-Kit Adult patients with ASM without the D816V c-Kit 
mutation or with c-Kit mutational status unknown. 
Patients with Kit (CD117) positive unresectable 
and/or metastatic malignant GIST. Adjuvant 
treatment of adult patients following resection of 
Kit (CD117) positive GIST. 
Effectivity Tumor 
 Ph+ Newly diagnosed patients with Ph+ CML in CP. 
Patients with Ph+ CML in BC, AP, or in CP after 
failure of interferon-alpha therapy. Adult patients 
with relapsed or refractory Ph+ ALL  
Effectivity Blood 
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PDGFR gene 
re-
arrangements 
Adult patients with MDS/MPD disease associated 
with PDGFR gene re-arrangements 
Effectivity Blood 
FIP1L1-
PDGFRα fusion 
Adult patients with HES and/or CEL who have the 
FIP1L1-PDGFRα fusion kinase (mutational analysis 
or FISH demonstration of CHIC2 allele deletion) 
and for patients with HES and/or CEL who are 
FIP1L1-PDGFRα fusion kinase negative or 
unknown 
Effectivity Blood 
Irinotecan   
 UGT1A1 A reduction in the starting dose by at least one level 
of CAMPTOSAR should be considered for patients 
known to be homozygous for the UGT1A1*28 allele
Toxicity Blood 
Lapatinib   
 Her2/neu Hormone receptor positive metastatic breast cancer 
that overexpresses the HER2 receptor for whom 
hormonal therapy is indicated. 
Effectivity Tumor 
Lenalidomide   
 Chr.5q Chromosome 5q deletion Effectivity Blood 
Mercaptopurine   
 TPMT Substantial dose reductions are generally required 
for homozygous-TPMT deficiency patients and for 
heterozygous patients when clinical evidences of 
severe toxicity, particularly myelosuppression, 
TPMT testing should be considered. 
Toxicity Blood 
Nilotinib   
 Ph+ Patients positive for Philadelphia chromosome Effectivity       Blood 
 UGT1A1 Tasigna can increase bilirubin levels. A 
pharmacogenetic analysis the (TA)7/(TA)7 
genotype was associated with a statistically 
significant increase in the risk of hyperbilirubinemia 
relative to the (TA)6/(TA)6 and (TA)6/(TA)7 
genotypes. 
Toxicity Blood 
Panitumumab   
 EGFR Detection of EGFR protein expression is necessary 
for selection of patients. 
Effectivity Tumor 
 KRAS Use of Vectibix is not recommended for the 
treatment of colorectal cancer with in patients 
whose tumors had KRAS mutations in codon 12 or 
13. 
Effectivity Tumor 
Rasburicase   
 G6PD Do not administer Elitek to patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency.  
Toxicity Blood 
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Tamoxifen   
 Estrogen 
receptor 
Available evidence indicates that patients whose 
tumors are estrogen receptor positive are more 
likely to benefit from NOLVADEX therapy. 
Effectivity Tumor 
Thioguanine   
 TPMT Inherited deficiency of the enzyme thiopurine 
methyltransferase (TPMT) may be unusually 
sensitive to the myelosuppressive effects of 
thioguanine and prone to developing rapid bone 
marrow suppression following the initiation of 
treatment.   
Toxicity Blood 
Tositumomab   
 CD20 antigen The BEXXR therapeutic regimen is indicated for the 
treatment of patients with CD20 antigen expressing 
relapsed or refractory, low grade, follicular, or 
transformed non-Hodgkin´s lymphoma, including 
patients with Rituximab-refractory non-Hodgkin´s 
lymphoma.   
Effectivity Blood 
Trastuzumab   
 Her2/neu Detection of HER2 protein overexpression is 
necessary for selection of patients appropriate for 
Herceptin therapy. 
Effectivity Tumor 
Warfarin   
 CYP2C9  
VKORC1 
Not all factors causing warfarin dose variability are 
known. The maintenance dose needed to achieve a 
target PT/INR is influenced genetic factors 
(CYP2C9 and VKORC1 genotypes) patients. Dose 
adjustments are required. 
Effectivity Blood 
Table 1. Pharmacogenomic Biomarkers in Drug Labels in Oncology-Hematology labeled by 
FDA 
In line with the pharmacogenetic markers are the pharmacogenetic methods used to test 
them. A review by Beaulieu et al., make an analysis of the evaluation of the 
pharmacogenomic tests implemented by some organizations. The authors state: A high 
degree of heterogeneity between evaluations was observed even within studies evaluating 
the same pharmacogenomic test¨ (Beaulieu et al., 2010). 
Interestingly, of the 44 markers analyzed by the review, only the analysis of HER-2 gene 
amplification and HER-2 protein overexpression related to the breast cancer treatment, 
Trastuzumab, and EGFR overexpression related to NSCLC treatment, Erlotinib, was 
assessed or referred by the four organizations mentioned, and there is only 7 and 10 markers 
that were evaluated by three and two of them, respectively. This reflects the lack of 
consensus in the genetic markers utilized for the pharmacogenetic approach of the 
treatments (Beaulieu et al., 2010). 
The analysis, realized by the authors, highlights some issues in some of the studies, like, the 
poor definition of the genetic group classification used for the evaluation of the markers, as 
well as the management of the possible false results that were not considered in some of 
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them. In one of the studies, the authors used inappropriate information to infer the 
genotype, and in another there is not a clear presentation of the drug dose administrated 
based on the genetic data. The authors pointed out the need of a confirmatory assay for the 
evaluation of the markers when a standardized screening method do not exist, confirmation, 
that it is not always performed. Finally, they underline the confusing assignment of the 
intermediate phenotype that can lead to a wrong classification of the patients into the 
groups (Beaulieu et al., 2010). 
Regardless these polymorphisms seem to be implicated in the treatment outcome, the lack 
of replication of these studies together with the fact that most replicated studies are done in 
tumor samples, bring in relevance the importance of the study of the tumoral tissue 
(Contopoulos-Ioannidis, 2006; FDA, 2011). 
If following the stated lines for this approach, it appears evident that the optimal situation 
would be the analysis of tumor samples at different times in order to provide updated 
information enabling a better treatment selection, as it is already done in different leukemias 
(Baccarani et al., 2006). 
However, the difficulty of this practical approach in solid cancers point out the importance 
of defining the somatic footprinting of the tumor. 
Since each tumor has its specific genetic pattern that could be modified because of the 
addition of new variables, we seek to evaluate the impact of cancer treatments in the 
modulation of these patterns. 
With this aim, following our previous study, where pharmacogenetic markers were studied 
in pre-treatment tumoral samples, we studied post-treatment tumoral samples in the same 
cohort of patients with the purpose of try to establish the direction of the somatic mutations 
under the influence of cancer treatment that we expect will help us, in the future, to find out 
to find out the mutational mechanisms trigger in rectal cancer that have an impact in the 
pharmacogenetics markers (Balboa et al., 2010). 
1.2 Molecular events produced in a rectal cancer  
Even though the adenoma-carcinoma sequence drives the colorectal cancer development 
(Gloor, 1986), specific molecular events differentiate rectal versus colon cancer (Lindblom, 
2001). The proximal colon tumor is more prone to microsatellite instability than rectal and 
distal areas, whereas distal and rectal colon tumors have been associated with chromosomal 
instability and microsatellite stability (Li & Lai, 2009; Fernebro et al., 2002; Gervaz et al., 2004).  
Other genetic alterations, such as over-expression of TP53 and COX-2 genes, and the pattern 
of mutational frequencies or chromosomal alterations can explain the worse prognosis of 
patients with rectal cancer (Slattery et al., 2009), but it is noteworthy that patients with 
different tumors but similar genetic and molecular background seem to have similar 
survival (Kalady et al., 2009). 
In the same way, the existence of mutually exclusive mutations in the same tumor type 
highlights the importance of differentiate subgroups. These observations reveal the 
importance of identify the tumor specific genetic pattern (Yeang et al., 2008). 
1.3 Pharmacogenomics of Neoadjuvant chemoradiation in rectal cancer  
5-Fluorouracil (5-FU), is an antimetabolite of the pyrimidine analogue type which inhibits 
the DNA and RNA synthesis. The main target for 5-FU is Thymidylate synthase (TYMS); 5-
FU acts preventing methylation of the deoxyuridine monophosphate (dUMP) to 
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deoxythymidine monophosphate (dTMP) by forming a stable complex 5-FU-TYMS, causing 
a thymine deficiency (Zhang, 2008). The methylation reaction requires the availability of 
methyl donors, in this case the 5,10-methylenetetrahydrofolate (CH2THF), which 
concentration is regulated by several enzymes such as Methylenetetrahydrofolate Reductase 
(MTHFR) (Gaughan et al., 2000). Since 80-85% of drug catabolic degradation occurs in the 
liver by Dihydropyrimide dehydrogenase (DPYD) (Ho et al., 1986), deficiency of this 
enzyme leads to toxicity that can cause death (Johnson et al., 1999). Both the level of TYMS 
expression (Pullarkat et al., 2001) and the degree of activity of MTHFR (Cohen et al., 2003) 
have been associated with treatment effectiveness and toxicity, although the latter is mainly 
related to DPYD activity (Johnson & Diasio, 2001).   
Radiotherapy uses ionizing radiation to induce cellular damage either directly or indirectly, 
through interactions with water-derived radicals causing in DNA both, single-strand breaks 
and double-strand breaks. Cells that are exposed to radiation start a process that ultimately 
activate cell cycle checkpoints allowing DNA enzyme repair activity; when DNA damage can 
not be repaired, cells undergoes apoptosis (Pawlik & Keyomarsi, 2004; Hoeijmakers, 2001). In 
accordance with the damage generated, different repair systems are working in cells 
(Hoeijmakers, 2001). Single strands breaks are repaired by a rapid global single-strand breaks 
repair process, being XRCC1 one of the most important proteins that mediate this process by 
acting as a molecular scaffold stabilizing and promoting different steps of the single-strand 
breaks repair process (Caldecotto, 2003): XRCC1 acts direct and indirect by interaction with 
other molecules in the end processing, gap filling and ligation. Double-strand breaks are 
repaired by non homologous end-joining, homologous recombination and single-strand 
annealing, being this kind of damaged which generally leads to a lethal event (Valerie & 
Povirk, 2003). ERCC1 is an endonuclease of the nucleotide excision repair system that acts not 
only in the single-strand annealing repair but also there are evidences that acts in the 
homologous repair of the double strand break (Murray & Rosenberg, 1996; Niedernhofer et al., 
2004; Ahmad et al., 2008). Deficiency in this enzyme, and others implicated in the NER system, 
has also been associated with hypersensitivity to radiation (Parshad et al., 1993; Satoh et al., 
1993). One of these enzymes, ERCC2, is implicated in the repair of numerous types of damage 
and although there are few data on the possible connection between this gene and 
radiotherapy response it has been hypothesized to participate in the repair of ionizing 
radiation damage (Rzeszowska-Wolny et al., 2005; Angelini et al., 2005). 
Although the volume of the literature on pharmacogenetic markers involved in the response 
to 5-FU is quite large (Strimpakos et al., 2009; Huang & Ratain, 2009), there are still few 
studies examining the relationship between pharmacogenetic markers and response to 
chemoradiotherapy (Lamas et al., 2009), with most of them focused on p53, Ki-67, p21, and 
bax/bcl-2 (Smith et al., 2006; Debucquoy et al., 2006; Kuremsky et al., 2009), cytochrome c 
oxidase II (COX-2) (Debucquoy et al., 2006), EGF receptor (EGFR) (Kikuchi et al., 2009) and 
TYMS (Kikuchi et al., 2009; Stoehlmacher et al., 2008). A summary of the principal genes 
studied in relation to rectal cancer are shown in Table 2. However, the clinical utility of these 
biomarkers remains controversial (Kuremsky et al., 2009), with EGFR, p21 and TYMS as the 
most validated markers of response until now (Kuremsky et al., 2009).  
At the present germline-based pharmacogenetics is useful for predicting toxicity, but has 
serious limitations for the prediction of treatment response. As stated in a previous study, 
pharmacogenetic markers should be contrasted with the mutational pattern in each 
particular tumor type. The study of the tumor and, more specifically, the determination of 
the tumoral mutational spectrum can possible improve response prediction. 
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Gene Cell function Mutation or 
polymorphism 
Effect Hypothesis to test * 
P53     
 Implicated in genetic 
stability, cell proliferation, 
apoptosis, and inhibition of 
angiogenesis. 
Inactivating 
tumor 
mutations 
Increased 
genetic 
instability and 
survival of 
cells with 
damaged DNA 
Loss of p-53 
dependent apoptosis 
and a proliferation 
advantage. Mutant 
p53 resistant to CRT  
Ki-67     
 Asses proliferation.    
p21     
 Cyclin-dependent kinase 
inhibitors that inhibit cells 
from entering the G1 to S 
phase. 
Tumor 
mutations 
 Wild-type p21 
suppresses apoptosis 
in the presence of 
DNA damage caused 
by CRT  
bax/bcl-2    
 BAX is a proapoptotic 
counterpart of Bcl-2 which 
inhibits cellular apoptosis. 
Bax and Bcl2 
expression 
 Protect cells from 
radiation-induced 
apoptosis 
cytochrome c oxidase II 
(COX-2) 
   
 Catalyzes the conversion of 
arachidonic acid to 
prostaglandins. These 
factors are important 
mediators of tumor 
invasiveness and metastatic 
potential.
COX-2 over-
expression 
 Protect tumor cells 
from damage by 
generating 
prostaglandins as 
tumor survival factors 
*(Kuremsky et al., 2009; Gaya Spoverato et al., 2011; Davis et al., 2004) 
D
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g
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Gene 
Cell 
function 
Mutation or 
polymorphism 
Effect 
Hypothesis to 
test 
TYMS    
 DNA synthesis 
5´ 28-bp repeat 
(rs34743033) 
More repetitions increase the 
efficiency of translation (Horie 
et al., 1995) 
TS protein levels 
inversely 
associated with 
tumor clinical 
response 
(Kawakami et al., 
2001) 
 
SNP G->C 
(rs2853542) 
High- and low-expression 
haplotypes (Johnston et al., 
1994; Mandola et al., 2003) 
  High: 2R/3G,3C/3G,3G/3G Increased 
survival in low-
expression 
groups (Mandola 
et al., 2003; 
 Low: 2R/2R, 2R/3C, 3C/3C 
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Kawakami &  
Watanabe, 2003) 
  
TS1494del6 
(rs16430) 
Decreases the stability of mRNA 
(Mandola et al., 2004) 
Protective role in 
adjuvant 
treatment (Dotor 
et al., 2006) 
DPYD    
 Drug catabolism
DPYD*2 
(IVS14+1 G->A) 
(rs3918290) 
Decreased activity by deletion 
of exon 14. (van Kuilenburg et 
al., 2002) 
 
MTHFR    
 Implicated in the 
regulation of the 
concentration of 
methyl donors 
SNP C677T 
(rs1801133) 
The change Val222Ala leads to a 
thermolabile variant of MTHFR 
with reduced enzymatic activity 
(Frosst et al. 1995) 
Increased 
sensitivity to 5-
FU  (Sohn et al., 
2004; Etienne et 
al., 2004) 
 
SNP A1298C 
(rs1801131) 
The change Glu429Ala results in 
decreased MTHFR activity 
(Weisberg et al., 1998) 
 
 
 
Gene Cell function 
Mutation or 
polymorphism
Effect 
Hypothesis to 
test 
R
a
d
io
th
e
ra
p
y
 
C
e
tu
x
im
ab
 
EGF receptor (EGFR)    
 
Cell proliferation, apoptosis, and 
differentiation 
EGFR 
overexpression 
Approximately 
80% inhibition in 
alleles with 21 
CA repeats 
(Gebhardt et al. 
1999) 
Response to 
preoperative 
radiotherapy 
(Giralt et al., 
2002)  
 
 
CA-SSR1 
(rs11568315) 
R
a
d
io
th
e
ra
p
y
  
   
  
O
x
a
li
p
la
ti
n
 
XRCC1    
 
Protein that acts as a molecular 
scaffold, stabilizing and 
promoting different steps of the 
SSB repair process, directly and 
indirectly by interacting with 
other molecules in the end 
processing, gap filling and 
ligation. 
Arg399Gln 
(rs25487) 
Changes in 
binding capacity 
in the protein 
with the mutated 
allele to proteins 
that interact with 
it (Evans et al., 
1997) 
Ionizing 
radiation 
hypersensitivity 
(Hu et al., 2001) 
 
Resistance to 
oxaliplatin 
(Stoehlmacher et 
al., 2001) 
ERCC1   
 
Endonuclease of the nucleotide 
excision repair system that acts 
in the single-strand annealing 
repair, there is also evidence 
suggesting that ERCC1 acts in 
the homologous repair of 
double-strand breaks 
Asn118Asn 
(rs11615) 
Predicts 50% 
decrease in the 
efficiency of 
translation of 
mRNA to protein 
(Lunn et al., 
2000) 
Ionizing 
radiation 
hypersensitivity 
(Lamas et al., 
2009) 
 
Resistance to 
oxaliplatin 
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(Stohelmacher et 
al., 2004) 
ERCC2 (XPD)    
 
Implicated in the repair of 
numerous types of damage. 
Although there are few data on 
the possible connection between 
this gene and radiotherapy 
response, it has been 
hypothesized to participate in 
ionizing radiation repair damage
Lys751Gln 
(rs13181) 
The wild-type 
allele exhibits 
suboptimal 
radiation-
induced damage 
repair (Lunn et 
al., 2000) 
Possible 
predictor of 
clinical outcome 
(Zárate et al., 
2006) 
 
Resistance to 
oxaliplatin (Park 
et al., 2001) 
Table 2. Pharmacogenetic biomarkers in rectal cancer treatment. 
2. Material and methods  
2.1 Patients & clinical data 
We studied germline and tumoral samples of 65 stage II/III rectal patients. They were 
staged by CT scan, colonoscopy and endorectal ultra-sonography. The tumors were assessed 
by biopsy. Every treatment began in the 3 weeks following diagnosis and staging. The 
patients received 5-FU 225 mg/m2/day continuous infusion or capecitabine 825 mg/m2 
twice daily during weeks 1–5, along the fractionated radiotherapy schedule (1.89 Gy per 
day, 50.49 Gy over the whole treat-ment). The surgery was carried out 6–8 weeks after 
completion of chemoradiotherapy using the TME technique. The surgical procedure 
included abdominoperineal resection, anterior resection and Hartmann’s operation. 
Tumor regression was assessed using the tumor regression grading (TRG) system of 
Mandard et al, 1994. as follows: 
TRG1: absence of residual cancer and extensive fibrosis; 
TRG2: rare residual cancer cells scattered through the fibrosis; 
TRG3: increased residual cancer cells but fibrosis still predominating; 
TRG4: residual cancer outgrowing fibrosis; 
TRG5: absence of regressive changes. 
Tumors were classified as good responders (TRG1 and TRG2) or poor responders (TRG3, 
TRG4 and TRG5). All patients gave written informed consent. 
Relevant clinical data were obtained from clinical records (gender, age, TRG and treatment). 
Response to treatment and overall survival were also analyzed. TRG was assessed by the 
pathologist in the surgical specimen.  
2.2 Genotyping 
Genomic DNA was extracted from paired peripheral blood samples and rectal cancer 
tumors. Blood was obtained before any treatment began, and the tumor used for genotyping 
was a sample from the initial biopsy. Germline DNA was obtained from leukocytes by 
peripheral blood samples using a magnetic particle-based purification kit (Chemagen, 
Baesweiler, Germany). Tumoral DNA was extracted from formalin-fixed, paraffin-
embedded sections of the tumor samples after xylene treatment. DNA extraction was 
performed using the QIAamp® DNA Mini Kit Extraction Column (Qiagen®, CA, USA) in 
accordance with the protocol. The DNA obtained was rapidly frozen at -20°C. 
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2.3 Pharmacogenetic polymorphisms 
We analyzed a panel of pharmacogenetics markers with previous evidence of relation or 
possible relation with the treatment currently used in rectal cancer. The pharmacogenetic 
markers analyzed were polymorphisms in XRCC1, ERCC1, ERCC2, GSTP1, MTHFR and 
DPYD gene, indicated in Table 2. 
2.4 SNaPshot assay 
Polymorphisms at XRCC1, ERCC1, ERCC2, GSTP1, MTHFR and DPYD were analyzed by 
the SNaPshot® (SNaPshot Multiplex System, Applied Biosystems, CA, USA) method. 
Multiplex PCR primers and SNaPshot probes and methods were previously described 
(Balboa et al., 2010).  
3. Results 
Genotyping analysis was performed in 65 enrolled patients of rectal cancer. Their 
characteristics are shown in Table 3. Median age of the patients was 64 years (range 37-85) 
and all were submitted to total mesorectal excision (TME). Surgery was scheduled 6-8 weeks 
after completion of radiochemotherapy. Median time from the end of neoadjuvant treatment 
and surgery range from 5 to 13 weeks using the total mesorectal excision technique. Patients 
were divided into two groups according to the neoadjuvant-surgery interval: <8 weeks and 
≥8 weeks. Forty-six patients in this study had an interval to surgery ≥8 weeks. Of that group, 
20 (43.48%) were good responders. Nineteen patients underwent surgery at an interval <8 
weeks and 11 (57.9%) of them were good responders.  
 
Gender Female 15 (23.1%)
 Male 50  (76.9%)
Age     
 Median (years) 64  
 Range (37-85)  
    
Clinical Stage    
 II 20 (30.8%)
 III 45 (69.2%)
    
Tumor localization    
 Rectal 65 (100%)
TRG 1 19 (29.2%)
 2 12 (18.5%)
 3 20 (30.8%)
 4 10 (15.4%)
 5 4 (6.1%) 
    
Neoadjuvant therapy    
    
  FU/UFT+RDT       46 (70.8%)
 CAPECIT+RDT      19 (29.2%)
Table 3. Characteristics of the 65 patients 
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As reported previously (Balboa et al., 2010) no significant associations were observed 
between good responders in patients operated before 8 weeks compared to those operated 
after 8 weeks, p=0.297, OR=1.798. The surgery procedure included anterior resection in 39 
patients, abdominoperineal resection in 23 patients and Hartman procedure in 3 patients. A 
histopathologically confirmed complete resection (R0 status) of proximal and distal 
resection margins was achieved in 62 cases. Tumor regression parameters became apparent 
by T-level downsizing (comparing pretreatment cT with ypT at surgery) in 46 patients 
(70.8%). T-level was decreased by one level in 21 patients (32.3%), two levels in 6 patients 
(9.2%), three levels in 15 patients (23.1%) and four levels in 4 patients (6.2%). UICC 
downstaging (comparing cUICC and ypUICC) was performed in 49 patients (75.4%).  
Sixty-five patients were evaluable for pathological response. Pathological staging was as 
follows: ypT0N0 19 patients (29.2%), ypT1N0 4 patients (6.2%); ypT2bN0 18 patients 
(27.7%); ypT2N1 1 patient (1.5%) and ypT3 in 23 patients (35.4%) (N0:11, N1:10; N2:2).  
Complete pathologic response TRG1 was observed in 19 (29.2%) of patients and TRG2 was 
observed in other 12 (18.5%) patients, so the good response rate was of 47.7% in this study. 
Of the remaining 52.3% of patients, 20 patients (30.8%) showed TRG3, 10 patients (15.4%) 
TRG4 and 4 patients (6.1%) showed TRG5.  
From 65 patients initially studied we obtain tumor samples after treatment in 53 cases. 
Germline DNA from blood, biopsy samples DNA (T0) and surgical samples DNA (T1) from 
the patients were genotyped for XRCC1, ERCC1, ERCC2, GSTP1 and MTHFR gene 
polymorphisms. Genotype distribution in blood is in agreement with that predicted by the 
Hardy-Weinberg equilibrium. Overall frequencies of the studied polymorphisms were found 
to be similar to those described in previous reports. A summary of results are in Table 4. 
 
  Blood T0 T1 
XRCC1 A/A 3  5   1 
 G/A 33  42  34 
 G/G 29  16 17 
ERCC1 C/C 7   3  4 
 C/T 31  33 24 
 T/T 27  29  23 
ERCC2 A/A 23  24  17 
 A/C 38  39  33 
 C/C 4   1   1 
GSTP1 A/A 36 30 26 
 G/A 23 21 13 
 G/G 6 6 5 
MTHFR_C677T C/C 30  26  19 
 C/T 27  28 26 
 T/T 8 11  7 
MTHFR_A1298 A/A 28  23  20 
 A/C 27  35  24 
 C/C 10 7   9 
Table 4. Genotypes in blood, biopsy (T0) and tumor after treatment (T1)  
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In Balboa et al. (2010) we described the differences between the genotypes when blood and 
biopsy are analyzed. When blood sample is used a significant association with response to 
treatment is given with TS gene 5'UTR, but this significance is lost in the analysis of biopsys, 
arising an association between better response and genotype AA of XRCC1 gene. However, 
many differences between the genotype determined in blood and tumor samples were 
found. Loss of heterozygosity but no microsatellite instability was observed in the study. 
Some patients, harbouring several mutations and high somatic mutational rate allow us to 
classify them as hipermutable. The C:G to T:A transitions was the most prevalent changes 
and C:G to G:C transversions more rare, these percentages, that are conditioned by the 
initials genotypic frequencies of each gene in the patients cohort, it is driven by the specific 
mutational mechanisms asociated to each gene in each tumor.  
By contrast XRCC1 appeared significant due to the increase of allele A, as results of the 
transition C:G to T:A. The latter could not happen with the ERCC1 presumably because the 
allele involved is the C, and that allele is the least frequent. This loss will have little effect on 
the association analysis, even if such association actually exists. 
Table 5 and 6 show the results, of the study of these same patients cohort, after treatment.  
As we can observe the tumor after treatment genotypes are more similar to the germline 
(blood), related to the effectiveness of treatment, able to reverse the genotypes. However a 
more detailed analysis of data reveals interesting aspects. First, although the genotypes of 
T1 tumor are more similar to blood, this effect is more pronounced for LOH than for gain of 
alleles. Yet, for almost all the markers after treatmen we reveal a drop of LOH to 0% except 
ERCC1 (4.5%) and MTHFR C677 (4.3%). In contrast, individuals who were homozygous in 
blood and heterozygotes in biopsy (16.9% average, with range from 40% for XRCC1 gene to 
8,6% for GSTP1) are reduced in the second tumor in 11.6% (reduction in MTHFR is more 
pronounced (Balboa et al., 2010). 
Thus, regardless of the specific tumor marker and taking into account the possible influence 
of tissue analyzed (more or less rich in tumor cells) we can broadly see in that reduction of 
genotype differences (which can be attributed to a reduction of tumor tissue related to 
tumoral treatment), a clear distinction between the two underlying mechanisms: recovery of 
LOH and gain of alleles. So, regardless of whether the cells are actually affected by the 
treatment, is clear that this treatment affects more strongly the former mechanism than the 
latter. If we establish a connection between genomic instability and LOH versus altered 
sequence repair mechanisms and gain of alleles seems that a selection is occurring against 
the first mechanism and not so intense in the second, and the survival cells were those 
maintain this altered mutational mechanism. 
Taking a look at individual markers, it provides valuable information about previously 
proposed pharmacogenetic hypothesis. So for XRCC1 gene, we have 65 blood, 62 biopsy 
and 52 resection genotypes. From individuals that were homozygous analyzing blood, we 
can observe the 11 heterozygous genotypes (AG) in the biopsy analysis and 9 AG genotypes 
in the second tumor sample. The A allele is described as related to a ineffective protein and 
consequently associated to a more effective treatment. In our patients there are 4 individuals 
who revert to a normal (GG) genotype, which would be consistent with the hypothesis but 
an individual who reverts to AA. Since there have been a reduction in the tumor regression 
would be expected that cells with A allele would be greatly compromised in their ability to 
survive. If treatment is not completely effective in GG harbouring cells, the sample should 
be enriched with G alleles, but not with A ones. Furthermore, 3 individuals whose initial 
tumor was GG appear after treatment with GA. 
www.intechopen.com
 
Rectal Cancer – A Multidisciplinary Approach to Management 266 
 
 XRCC1 ERCC1 ERCC2 GSTP1 MTHFR_ MTHFR_ Total 
 (%) (%) (%) (%) C677 (%) A1298 (%) (%)4 
LOH1               
T0 3 9,1% 2 6,5% 3 8,1% 3 13,6% 6 22,2% 0 0,0% 17 30,4% 
T1 0 0,0% 1 4,5% 0 0% 0 0,0% 1 4,3% 0 0,0% 2 8,3% 
Gain of allele2           
T0 12 40,0% 4 11,8% 5 18,5% 3 8,6% 7 18,4% 8 21,1% 39 69,6% 
T1 9 32,1% 3 10,3% 3 15% 1 3,1% 4 13,8% 2 6,7% 22 91,7% 
Total3               
T0 15 23,8% 6 9,2% 8 12,5% 6 10,5% 13 20,0% 8 12,3% 56 100,0% 
T1 9 20,9% 4 9,5% 3 7,1% 1 2,7% 5 11,6% 2 4,5% 24 100,0% 
Table 5. Germline changes versus tumor changes (T0 and T1): loss of heterozygosity and 
gain of alleles in XRCC1, ERCC1, ERCC2, GSTP1 and MTHFR genes. 
 
 XRCC1 ERCC1 ERCC2 GSTP1 MTHFR_ MTHFR_ Total 
 (%) (%) (%) (%) C677 (%) A1298 (%) (%)4 
Substitutions at C:G base pairs        
C:G>T:A5             
T0 14 16,1% 6 13,3%   3 9,4% 10 11,5%   33 58,9% 
T1 9 11,5% 4 11,1%   0 0,0% 4 6,0%   17 70,8% 
C:G >A:T5             
T0     6,0 13,3%     3 6,4% 9 16,1% 
T1     2 5,6%     1 2,4% 3 12,5% 
Substitutions at T:A  base pairs          
T:A>C:G5             
T0 1 2,6% 0 0%   3 3,7% 3 7,0%   7 12,5% 
T1 0 0,0% 0 0%   1 1,5% 1 2,7%   2 8,3% 
T:A >G:C5             
T0     2 2,4%     5 6,0% 7 12,5% 
T1     1 1,5%     1 1,5% 2 8,3% 
Total6               
T0 15 26,8% 6 10,7% 8 14,3% 6 10,7% 13 23,2% 8 14,3% 56 100,0% 
T1 9 37,5% 4 16,7% 3 12,5% 1 4,2% 5 20,8% 2 8,3% 24 100,0% 
 
Table 6. Germline changes versus tumor changes (T0 and T1): single base substitutions in 
XRCC1, ERCC1, ERCC2, GSTP1, and MTHFR genes.  
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This case illustrates some of the issues involved in the pharmacogenetic studies: 
- Confounding factors. The coexistence of markers related to opposite associations could 
mask the results (Showalter et al., 2008).  
- The association to treatment efficacy may be a statistical artifact, in fact not related to 
the marker but to the mutational mechanism of the tumor. For example, as already 
described previously (Sjoblom et al., 2006; Balboa et al., 2010), in rectal cancer the C:C to 
T:A transitions are the most prevalent changes and consequently the new alleles arising 
will be mainly A (GG to GA, GA to AA genotypes) but not G (no cases of AA to GA 
genotypes). Thus, for this marker, the mutagenic mechanism related to the specific G to 
A changes, determine the appearance of this allele in the tumor and possibly the 
subsequent association. As we have seen this mutagenic mechanism remains in the 
tumor after cancer treatment. 
Yeang et al. (2008) detected significant different mutational patterns between cell lines and 
tumor samples. The effect of a polymorphism or somatic mutation in a protein is firstly tested 
in a cell line. So, another confounding source in the pharmacogenetics studies is due to that 
data supporting their functional effect come from ¨in vitro¨ studies and the effect observed of 
these mutations or polymorphisms in the cell lines could not be the same ¨in vivo¨. When these 
markers are tested in patient samples studies a lack of replication has been observed. 
Quantification of the mutations along the different stages could helps us to identify the 
effective mutations, since it is expected an increase in the population of the cells that carry 
beneficial mutations for the tumor along the cancer development, but these increase in the 
number of cells that carry somatic mutations in one stage, but that are not kept across the 
stages could be explained too by a momentary increase of the uncontrolled cell population 
that are going to die due to the high number of harmful mutations.   
4. Discussion  
The difficult of analyzing tumor samples rises from the heterogeneity found in cancer cells 
that are subdue to different conditions depending on its location in the tumor (Michor et al., 
2010). Besides, tumor samples are a mixture of these differents tumor cells and normal cells 
(Biankin & Hudson, 2011). These circumstances explain the difficult of interpret the results 
of pharmacogenetic markers in tumor samples. 
To analyze tumor samples is important to differentiate too, the genetic background of the 
patient from the genetic of the tumor, and differenciate these from the response of the 
tumors to the treatment. 
Tumor have an inherent progression, even though this is going to be affected by the 
patient´s genetic background, there are a pattern of genetic alterations, typical of each 
tumor. So, when a gene, that are tested in pharmacogenetic studies, is implicated in cancer 
progression, even though it should be expected a similar trend between patients, different 
results could be obtained, that are related to the different circumstances that the cells 
analyzing are being subjected.  An example of this is p53, a gene implicated in the adenoma-
carcinoma sequence. Overexpression of this gene has been linked to rectal cancer but, 
analysis of the tumor has shown different expression rates measure by IHC (Kuremsky et 
al., 2009; Gaya Spoverato et al., 2011). Another example of this is the proliferating cell 
nuclear antigen (Ki-67) used to assess cell proliferation. A cancer actively growing should 
have high Ki-67 expression but these will be depending on the stage, the status and the 
localization of the cells being tested.   
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Another important point to take into account is that even though cancer treatments are design 
to act mostly over high proliferative tumor cells, this is dependent of the genetic background 
of cell tumor. So, although it should be expected that a tumor with high cell proliferative rates, 
should experience higher efficiency and have a better prognostic, different results can be 
obtained, depending on the genetic background of cell tumor. If we take as example the 
meaning of the results of Ki-67, it should be expected that cells with a high proliferative rate, 
have a high Ki-67 expression, and experience a high treatment efficiency with a good 
prognostic, but studies by IHC show contradictory results or no correlation with the 
prognosis, indicating that in tumor cells are being produced a set of different changes that lead 
to achieve a result which are not explained by the analysis of single markers.(Kuremsky et al., 
2009; Gaya Spoverato et al., 2011) 
So, to interpret the results from pharmacogenetics studies and to extract information from 
them, it is of main importance understand the circumstances to which tumor are subjected, 
and identify the driver mutations, that are produced on them, that will lead its developed 
and its response to the environment (Stratton et al., 2009) 
4.1 Ecology of the cancer 
All biological system is affected by the interaction of the environment that surrounds it, and 
it is the response to signals from that environment a major factor that determines the system 
behavior (Kenny et al., 2006; Crespi & Summers, 2005). 
Tumors, as any other biological system, need to survive and proliferate using the resources 
from their environment. Thus, the environment, where the different cancers are submerged, 
will shape the pathways that will be chosen by the cancer for its development. And, the 
response to the different signals received from the different environments over the 
progression of the cancer will configure the adjustment of the molecular pathways. These 
adjustments are executed at different levels, being the genetic level the first step of 
regulation, mainly through somatic mutations and epigenetic. (Stratton et al., 2009) 
In this sense, a plethora of mutational events are shared in cancer but the predominance of 
one over the others is the specific hallmark of each cancer. Identify and determine the 
meaning of the changes in these molecular pathways in each cancer is key for understand 
the mechanisms of cancer progression (Slattery et al., 2009). 
With this purpose, tumors have to redirect molecular pathways highly organized and 
controlled by many checkpoints in order to escape from the self-defense mechanisms, 
apoptosis, and grow in a not favorable environment. To achieve this aim, cells undergo 
changes at both phenotypic and genotypic levels that allow cancer cells to overgrow normal 
cells. 
Even within the tumor, cells are subjected to different conditions due to a differential 
oxygen pressure and nutrients input. These conditions determine the adjustments that cells, 
according to their localization, have to undergo within the tumor. As the tumor grows, cells, 
in the core of the tumor, experience a decrease in oxygen and nutrients contribution due to a 
lack of blood supply. These restricted circumstances cause the switch to an anaerobic 
metabolism which increase the genetic instability in the cells and induce the segregation of 
angiogenesis proteins (Allen & Louise Jones, 2011). 
At the same time, when tumor gets to a critical mass and the conditions for its development 
have been exhausted, cells in the tumor periphery initiate changes for its migration to 
localizations where conditions are more favorable.  In this transforming process, cells are 
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subject to a stochastic number of mutations that have a different fitness for the cell. Harmful 
mutations will inevitably cause cell death and beneficial mutations will be more or less 
efficient depending on in which cells and moment these mutations happen (Bindra et al., 
2005) 
But not only the tumor undergoes changes, this interaction is exerted in both ways, the 
tumor induces a transformation of its environment for its own benefit, inducing changes in 
the normal cells that support it (genetic alterations in the normal stroma have also been 
reported) (Kurose et al., 2001; Nosho et al., 2010). Not only cells from the stroma, hypoxia 
also plays a role in determining the phenotype of infiltrating monocytes, which have an 
impact on tumor cell behavior, since the inflammatory response have an effect in tumor 
progression, that can be either pro-tumoral or anti-tumoral (Allen & Louise Jones, 2011). 
5. Concluding remarks 
As the cancer evolves, different mechanisms drive their progression. The introduction of an 
additional variable as it is cancer treatments should have an important impact in cancer 
behavior.  
Cancer treatment research, try to identify specific hallmarks of cancer cells that could 
differentiate them from healthy cells in order to avoid the adverse effects when these 
treatments are given to the patients. These differential features, can be the formation of new 
chromosomal entities as it happens in some leukemias or can be a differential regulation of 
pathways at different levels that are already acting in normal cells. 
The importance of study the tumoral samples, before drug administration, raises from the 
fact that cancer treatments are design to exert their action in cells where these changes had 
happen.   
Introduction of cancer treatment cause a new alteration in the system, tumoral cells have to 
respond to a new adverse factor, so they again have to module their behavior in order to 
survive. Once the treatment is given to the patients, two mechanisms of selection should be 
acting in cancer cells, mechanisms of selection for tumor progression and mechanisms of 
selection to survive to cancer treatment.   
Cancer treatments have a percent of ineffectiveness that can be due to both, drug 
inefficiency or inaccurate dose so, the number of cells that persist under the treatments and 
the time that these cells dispose to rearrange the survival and proliferative pathways for its 
adaptation to the new conditions, will increase the probabilities of emergence of resistance 
cells to the drug administrated. Since cancer treatments are design to act principally in high 
proliferative cells, cells that have acquire the mechanisms to proliferate at a higher rate will 
be the more affected unless this cells posses any mechanisms to avoid it.  
The specific mutational pattern in each gene helps to understand their meaning and the 
impact of these changes in tumor´s behavior (Kim et al., 2008). Different mutational patterns 
in tumor progression respond to an adjustment of the tumor to the different conditions and 
stages, depending on the tumor´s needs, in that sense, different mutational patterns should 
be expected across the stages.  
This approach has been used in several studies, were tumors at different stages have been 
analyzed. In these studies persistence of somatic mutations detected in the primary tumor 
through the different stages has been observed, but at different frequencies, indicating, as 
stated Li Ding et al, that the metastasis arises from a minority of cells in the primary tumor 
(Ding et al., 2010).The analysis of post-treatment tumor samples helps to analyze if the 
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mutational mechanisms, produced during tumor development, that were analyzed in pre-
treatment samples, persist under the cancer treatment, and what changes the cells have 
undergone to be resistant to treatment. 
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